Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Ambarella surges after report says company exploring strategic options, including sale (SeekingAlpha) +++ AMBARELLA Aktie +15,53%

HALOZYME Aktie

 >HALOZYME Aktienkurs 
46.5 EUR    +2.0%    (Tradegate)
Ask: 46.49 EUR / 220 Stück
Bid: 46.4 EUR / 220 Stück
Tagesumsatz: 467 Stück
Realtime Kurs von 8 bis 22 Uhr!
HALOZYME Aktie über LYNX handeln
>HALOZYME Performance
1 Woche: -1,9%
1 Monat: -4,8%
3 Monate: -24,0%
6 Monate: +1,3%
1 Jahr: -4,4%
laufendes Jahr: -0,3%
>HALOZYME Aktie
Name:  HALOZYME THERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US40637H1095 / A0DLHS
Symbol/ Ticker:  RV7 (Frankfurt)
Kürzel:  FRA:RV7, ETR:RV7, RV7:GR
Index:  -
Webseite:  https://halozyme.com/
Marktkapitalisierung:  5840 Mio. EUR
Umsatz:  947.74 Mio. EUR
EBITDA:  590.77 Mio. EUR
Gewinn je Aktie:  2.896 EUR
Schulden:  1351.4 Mio. EUR
Liquide Mittel:  656.33 Mio. EUR
Umsatz-/ Gewinnwachstum:  35.2% / 53.7%
KGV/ KGV lG:  14.24 / 11.27
KUV/ KBV/ PEG:  6.36 / 13.68 / -
Gewinnm./ Eigenkapitalr.:  44.76% / 147.06%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  HALOZYME
Letzte Datenerhebung:  24.06.25
>HALOZYME Eigentümer
Aktien: 123.22 Mio. St.
f.h. Aktien: 121.83 Mio. St.
Insider Eigner: 1.17%
Instit. Eigner: 102.08%
Leerverk. Aktien: -
>HALOZYME Peer Group

 
20.06.25 - 19:18
 Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PR Newswire)
 
SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European......
16.06.25 - 17:30
 Here′s Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)
 
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....
04.06.25 - 13:00
 Zacks.com featured highlights Sterling Infrastructure, BJ′s Wholesale, Molina Healthcare and Halozyme (Zacks)
 
Sterling, BJ's, Molina, and Halozyme stand tall with robust earnings growth and high interest coverage in June picks....
28.05.25 - 22:06
 Halozyme to Participate at Upcoming Investor Conferences (PR Newswire)
 
SAN DIEGO, May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to participate and host investor meetings at the following investor conferences. Details on the......
28.05.25 - 20:30
 3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) (Zacks)
 
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes....
28.05.25 - 17:30
 Implied Volatility Surging for Halozyme Therapeutics Stock Options (Zacks)
 
Investors need to pay close attention to HALO stock based on the movements in the options market lately....
28.05.25 - 17:06
 Bristol-Myers wins EU nod for Opdivo injectable developed with Halozyme (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
28.05.25 - 15:24
 Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme′s ENHANZE (AFX)
 
NEW YORK CITY (dpa-AFX) - Halozyme Therapeutics, Inc. (HALO) Wednesday said that Bristol-Myers Squibb Company (BMY) received approval from the European Commission (EC) for a new subcutaneous (SC) ......
28.05.25 - 14:33
 Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications (PR Newswire)
 
Opdivo® is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union SAN DIEGO, May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received European Commission (EC) approval of a new......
15.05.25 - 13:00
 Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme (Zacks)
 
Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme have been highlighted in this Screen of The Week article....
13.05.25 - 16:12
 J&J, Halozyme cut at Leerink on price control risk for combo products (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.05.25 - 20:30
 3 Reasons Why Growth Investors Shouldn′t Overlook Halozyme Therapeutics (HALO) (Zacks)
 
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes....
09.05.25 - 19:45
 Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy? (Zacks)
 
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out....
08.05.25 - 17:30
 Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
 
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....
08.05.25 - 11:54
 Halozyme nach geplatzter Evotec-Übernahme – Aktie startet jetzt durch (Der Aktionaer)
 
Im November vergangenen Jahres hat US-Biotech-Unternehmen Halozyme Therapeutics mit der geplanten Übernahme von Evotec für Aufsehen gesorgt. Das Vorhaben ist zwar geplatzt, das Unternehmen befindet sich aber weiter klar auf der Erfolgsstraße. Die Aktie vollzog am Mittwoch einen satten Kurssprung....
07.05.25 - 19:45
 HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View (Zacks)
 
Halozyme reports better-than-expected first-quarter 2025 results. The company increases revenue guidance for 2025. Shares rise....
07.05.25 - 02:30
 Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
 
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Was man zu lang bedenkt, das wird bedenklich. - Sprichwort
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!